Please try another search
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. Shanghai MicuRx Pharmaceutical Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Zhiyue Li | 45 | - | Deputy GM, CFO, Board Secretary & Director |
Yuan Zhengyu | - | - | CEO & Chairman |
Jian Duan | 62 | - | Director |
Yan Jin | 46 | - | Supervisor |
Hongbin Zhou | 51 | - | Director |
Hanmei Huang | 43 | - | Independent Director |
Ying Luo | 53 | - | Supervisor |
Qun Bao | 46 | - | Independent Director |
Yu Miao | 36 | - | Director |
Liang Lu | 41 | - | Chairman of the Supervisory Board, Director of the Quality & Compliance Department |
Hong Yuan | 47 | - | Deputy GM, Chief Clinical Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review